Xiangxi Wang, Ph.D, Prof.
-
Principal Investigator
State Key Laboratory of Biomacromolecules, IBP
Research Interests: Innate immunity and host-pathogen interaction
Email: xiangxi@ibp.ac.cn
Tel: 010-64888806
Address: 15 Datun Road, Chaoyang District, Beijing, 100101, China
Chinese personal homepage
- Biography
2005.09 - 2009.06 B.S., School of Life Science, Sichuan University
2009.09 - 2014.06 Ph.D., Institute of Biophysics, CAS
2014.07 - 2014.10 Associate professor, Institute of Biophysics, CAS
2014.07 - 2016.03 Academic visitor, University of Oxford
2014.11 - Professor, Institute of Biophysics, CAS
Xiangxi Wang, New Cornerstone investigator, principal investigator and deputy director of the State Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences and secretary-general of the Biophysical Society of China. He received his bachelor's degree in biotechnology from Sichuan University in 2009, and his doctor's degree from the Institute of Biophysics, Chinese Academy of Sciences in June 2014. Since July 2014, he has been engaged in scientific research at the Institute of Biophysics, Chinese Academy of Sciences. He focuses on emerging and re-emerging major infectious viruses, closely aligning with major national public health needs, elucidating viral infection and host immune mechanisms, leading and practicing interdisciplinary research at the intersection of viral structural design, antibody repertoire analysis, and innovative vaccine development. He applies cutting-edge technologies and scientific discoveries to the development of innovative vaccines, promoting the research, development, and market approval of multiple vaccines against infectious diseases, and pioneering novel technologies and theories in precision vaccinology.
- Awards
National Award for Excellence in Innovation in 2026
New Cornerstone investigator in 2025
The Second Prize of the State Natural Science Award in 2025
Mao Yisheng Science and Technology Award in 2025
The First Prize of the Beijing Natural Science Award in 2024
C.C. Tan Life Science Innovation Award in 2023
The First Prize of the Beijing Science and Technology Progress Awards in 2022
The 17th China Youth Science and Technology Award in 2022
Top Ten Progresses in Chinese Sciences in 2022
Zhong Nanshan Youth Science and Technology Innovation Award in 2021
Chinese Academy of Sciences Young Scientist Award in 2020
Top Ten Progresses in Chinese Science in 2019
Top Ten Progresses in Chinese Life Sciences in 2018
- Membership in Academies & Societies
- 1. The Secretary-General of the Committee of Chinese Biophysical Society (2025-present)2. The Standing Director of the Committee of Chinese Biophysical Society (2025-present)3. The standing committee member of the Chinese Preventive Medicine Association Vaccine Clinical Research Committee (2020-2025)4. Editorial committee of Protein & Cell (2019-present)5. Associate Editor of Microbes & Immunity (2024-present)
- Research Interests
1. Immune mechanisms, cross-species transmission, and vaccine development of coronaviruses
Coronaviruses, influenza viruses, and other highly mutable viruses can escape host immune recognition through antigenic drift or shift, thereby diminishing the protective efficacy of conventional vaccines. There is therefore an urgent need for novel broadly protective vaccines to establish an effective population immunity barrier. Following natural infection or vaccination, viruses undergo directed evolution under the selective pressure of humoral immunity, achieving continued coexistence with the host through the emergence of updated mutant strains or the replacement of dominant circulating strains. Antibody repertoire analysis can reveal the developmental pathways of neutralizing antibodies, their targeted epitopes, and the mechanisms underlying broad-spectrum recognition, thereby providing a basis for optimizing the design of protective antigens for vaccines.
Our research group focuses on vaccine development against highly mutable viruses, integrating structural biology, virology, immunology, and bioinformatics. By modulating antigen-specific/broad-spectrum immune signals, we engineer immunogens to induce potent and broadly neutralizing antibodies. In parallel, we employ novel vaccine technologies (such as mRNA and nanoparticles) to enhance immunogenicity and prolong the duration of protection. Furthermore, we use AI-based antigen engineering to precisely direct the neutralizing antibody repertoire induced by immunogens, preferentially activating mature broadly neutralizing antibodies and enhancing cross-protective efficacy, thereby laying the foundation for the development of "universal vaccines."
2. Immune mechanisms and antibody repertoire profiling of ADE/VAERD-type viruses such as dengue virus/respiratory syncytial virus
Viruses such as DENV and RSV can exacerbate disease progression through antibody-dependent enhancement (ADE) or vaccine-associated enhanced respiratory disease (VAERD), making vaccines developed via conventional approaches prone to causing serious safety issues. The four serotypes of DENV can induce non-neutralizing cross-reactive antibodies that promote viral replication and aggravate disease upon secondary heterotypic infection, while early inactivated RSV vaccines caused severe immunopathological responses, with non-protective epitopes on the surface antigens potentially being a key contributing factor.
Our research group focuses on elucidating the immune mechanisms of ADE/VAERD-type viruses, tracking antibody repertoires, and designing safe vaccines. Using technologies such as high-throughput single-cell sequencing and deep mutational scanning, we systematically dissect the neutralizing antibody repertoire patterns induced by natural infection and vaccination in populations across different spatiotemporal backgrounds for DENV and RSV, and identify the detrimental immune signals and key protective epitopes underlying ADE/VAERD. By combining structural biology with AI-based protein design, we stabilize protective antigen conformations and shield against detrimental ADE signals, enabling immunogens to induce potent neutralizing antibodies with high affinity and low ADE risk while avoiding the generation of non-neutralizing antibodies. This work provides a theoretical basis and technical support for the development of safe and highly effective DENV and RSV vaccines, advancing efforts to overcome the vaccine safety challenges that have long plagued humanity.
3. Deciphering the protective antigen repertoire and eliciting robust protection against pathogens with complex antigenic composition such as African swine fever virus and herpesviruses
African swine fever virus (ASFV) possesses nearly 200 protein-coding genes, and its highly complex capsid and envelope proteins shape the immune responses induced by vaccines. Our research group is deciphering the protective antigenic epitopes of ASFV and the humoral and cellular immune mechanisms they mediate, which facilitates the identification of key immunogens and helps avoid the induction of non-protective immune responses. Herpesviruses such as HCMV, VZV, and HSV-2 can establish long-term latency in the host, undergo periodic reactivation, and evade immune clearance. Using high-throughput immunological approaches, our group profiles the serum antibody repertoires of infected populations, identifies protective antigen sets, and develops multivalent vaccines through AI-based protein design. In parallel, leveraging proprietary virus-like particle (VLP) and biomimetic immunogen display technologies, we construct nanoparticle vaccines that elicit potent and durable humoral immunity.
- Grants
- Selected Publications
2026
1. Zhai H#, Yu W#, Wang J#, Deng J#, Lei S, Zhou T, Li Y, Xu K, Ma M, Feng R, Hu Y, Ren L, Cao Y, Liu E*, Wang X*. Antibody cocktails based on the occupationally acquired immunity of pediatricians neutralize and confer protection against RSV and hMPV, Sci Transl Med, 2026, 18(837): eadz4170.
2. Liu P#, Xi Y#, Deng J, Luo S, Liu T, Ding C, Zhu Q, He L, Li M, Wang N*, Liu Y*, Wang X*. Designed nanoparticles enable multivalent display of influenza HA to drive rapid, potent, durable, and cross-reactive antibody responses, Protein Cell, 2026: pwag046.
3. Yu H#, Wang J#, Yue C#*, Yang X, Liu D, Zhu L, Mao X, Guo M, Song H, Hu Y, Wang X*, Huang Y*. An internationally circulating chikungunya virus lineage with distinct mutational signatures was associated with the 2025 outbreak in China, Protein Cell, 2026, in press.
4. Liu P#, Zhu Q#, Liu J#, Ma Z#, Mou G#, Yu Y, Liu C, Ma C, Si J, Yang X, Huang M, Liu Y, Sun Y, Yu X, Sun Y, Liu T, Yu L, Wang Q, Ma H, Lv Q, Li J, Bao L*, Cao Y*, Wang X*, Yan H*. Convergent use of aminopeptidase N receptor by hedgehog merbecoviruses, Nature Microbiology, 2026, in press.
5. Chen Y#, Liu P#, Qi F#, Wang Y#, Ren Y#, Chen Y#, Chen R, Zhang C, Chen J, Li Y, Wang L, Wang N, Jiao H, Ma X, Liu T, Yue C, Zhu Q, Mao X, Wang S, Veit M, Wang N, Zhang Y*, Zhao L*, Bao L*, Wang X*, Su S*. Cross-species Spillover of MERS-CoV-like mink Coronaviruses driven by key spike mutations and Countermeasures Development, Nature Microbiology, 2026, accept.
6. Liu P#, Yu J#, Liu T#, Liu Y*, Wang X*. Structure-guided stabilization of the HCMV pentamer enhances thermostability and neutralizing antibody responses, Signal Transduct Target Ther, 2026, accept.
7. Chen R#, Zhang C#, Qi F#, Cao L#, Deng J, Chen Y, Liu P, Ren Y, Li Y, Wang L, Li F, Deng R, Yu Y, Mao X, Xu K, Bao L*, Cao Y*, Zhang Y*, Wang X*. Determinants of expanded ACE2 species tropism for merbecoviruses and pan-hACE2 dependent coronavirus prophylaxis, Protein Cell, 2026 , accept.
2025
8. Li J#, Cao L#, Zhao Y, Shen J, Wang L, Feng M, Zhu M, Ye Y, Kormelink R, Tao X*, Wang X*. Structural basis for the activation of a plant bunyavirus replication machinery and its dual-targeted inhibition by ribavirin, Nature plants, 2025, 11(3): 518-530.
9. Yu Q#, Fu W#, Zhang Z#, Liang D#, Wang L, Zhu Y, Sun E, Li F, Bu Z*, Chen Y*, Wang X*, Zhao D*. The p15 protein is a promising immunogen for developing protective immunity against African swine fever virus, Protein Cell, 2025, 16(10): 911-915.
10. Chen Z#, Feng L#, Wang L#, Zhang L#, Zheng B#, Fu H, Li F, Liu L, Lv Q, Deng R, Xu Y, Hu Y, Zheng J, Qin C, Bao L*, Wang X*, Jin Q*. A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5, Signal Transduct Target Ther, 2025, 10(1): 14.
11. Jian F#, Wec AZ#, Feng L#, Yu Y, Wang L, Wang P, Yu L, Wang J, Hou J, Berrueta DM, Lee D, Speidel T, Ma L, Kim T, Yisimayi A, Song W, Wang J, Liu L, Yang S, Niu X, Xiao T, An R, Wang Y, Shao F, Wang Y, Pecetta S, Wang X*, Walker LM*, Cao Y*. Viral evolution prediction identifies broadly neutralizing antibodies to existing and prospective SARS-CoV-2 variants, Nature Microbiology, 2025, 10(8): 2003-2017.
12. Cao L#, Qu J#, Zhang C#, Chen R, Wang J, Fehlner-Gardiner C, Niezgoda M, Satheshkumar PS, Wang X*, Tsao E*. Structural basis for broad neutralization of rabies virus by an antibody cocktail SYN023, Emerg Microbes Infect, 2025, 14(1): 2547724.
13. Hu J#, Jia Z#, Wang M, Nie L, Fu W, Zhang Q, Qin H, Nie J, Xu X, Xu L, Wang F, Chen Y, Xing B, Li T, Li D, Li S, Xia N*, Wang X*, Huang W*. Establishing a universal IVRP method for quadrivalent HPV vaccines to replace in vivo potency tests, NPJ Vaccines, 2025, 10(1): 55.
14. Chi H#, Zhao SQ#, Liu YP#, Xiong XC#, Zhong X#, Suo XX, Huang XY, Yue C, Zhang JJ, Cong Z, Li N, Du FX, Chen T, Ma JR, Wang L, Ying B, Deng YQ, Yin JY*, Wang X*, Xue J*, Qin CF*. Efficacy and safety of an mRNA encoding neutralizing antibody against SARS-CoV-2 in non-human primates, Sci Bull (Beijing), 2025, 70(18): 2948-2952.
15. Zhang Z#, Feng R#, Zhang L, Yang Q, Chen X, Wang X, Nie C, Peng W, Wang X, Zhu L*, Guo Y*, Sun Z*. Discovery and molecular mechanism of potent neutralizing antibody from humanized mice with respiratory syncytial virus, PLoS Pathog, 2025, 21(11): e1013674.
16. Li Y#, Wang J#*, Zhang C, Zhang Y, Deng J, Zhang H, Li M, Wang F*, Wang X*. MAAD: multidimensional antiviral antibody database, Protein Cell, 2025, 17(6): 560-572.
2024
17. Liu P#, Yue C#, Meng B#, Xiao T#, Yang S#, Liu S#, Jian F, Zhu Q, Yu Y, Ren Y, Wang P, Li Y, Wang J, Mao X, Shao F, Wang Y*, Gupta RK*, Cao Y*, Wang X*. Spike N354 glycosylation augments SARS-CoV-2 fitness for human adaptation through structural plasticity, National Science Review, 2024, 11(7).
18. Yue C#, Liu S#, Meng B#*, Fan K#, Yang S#, Liu P, Zhu Q, Mao X, Yu Y, Shao F, Wang P, Wang Y*, Gupta RK*, Cao Y*, Wang X*. Deletion of V483 in the spike confers evolutionary advantage on SARS-CoV-2 for human adaptation and host-range expansion after a prolonged pandemic, Cell Research, 2024, 34(10): 739-742.
19. Zhu Q#, Liu P#, Liu S#, Yue C*, Wang X*. Enhancing RBD exposure and S1 shedding by an extremely conserved SARS-CoV-2 NTD epitope, Signal Transduct Target Ther, 2024, 9(1): 217.
20. Jia Z#, Wang K#, Xie M#, Wu J#, Hu Y#, Zhou Y#*, Yisimayi A, Fu W, Wang L, Liu P, Fan K, Chen R, Wang L, Li J, Wang Y, Ge X, Zhang Q, Wu J, Wang N, Wu W, Gao Y, Miao J, Jiang Y, Qin L, Zhu L, Huang W, Zhang Y, Zhang H, Li B, Gao Q, Xie XS*, Wang Y*, Cao Y*, Wang Q*, Wang X*. A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2, Protein Cell, 2024, 15(12): 930-937.
21. Feng L#, Sun Z#, Zhang Y#, Jian F, Yang S, Xia K, Yu L, Wang J, Shao F, Wang X*, Cao Y*. Structural and molecular basis of the epistasis effect in enhanced affinity between SARS-CoV-2 KP.3 and ACE2, Cell Discovery, 2024, 10(1): 123.
22. Wang Y#, Zhang Z#, Yang M#, Xiong X#, Yan Q#, Cao L#, Wei P, Zhang Y, Zhang L, Lv K, Chen J, Liu X, Zhao X, Xiao J, Zhang S, Zhu A, Gan M, Zhang J, Cai R, Zhuo J, Zhang Y, Rao H, Qu B, Zhang Y, Chen L, Dai J, Cheng L, Hu Q, Chen Y, Lv H, So RTY, Peiris M, Zhao J, Liu X*, Mok CKP*, Wang X*, Zhao J*. Identification of a broad sarbecovirus neutralizing antibody targeting a conserved epitope on the receptor-binding domain, Cell Rep, 2024, 43(1): 113653.
23. Zhao D#, Wang N#, Feng X#, Zhang Z#, Xu K, Zheng T, Yang Y, Li X, Ou X, Zhao R, Rao Z*, Bu Z*, Chen Y*, Wang X*. Transcription regulation of African swine fever virus: dual role of M1249L, Nature Communications, 2024, 15(1): 10058.
24. Yang D#, Wang N#, Du B#, Sun Z, Wang S, He X, Wang J, Zheng T, Chen Y, Wang X*, Wang J*. Structural insights into Semiliki forest virus receptor binding modes indicate novel mechanism of virus endocytosis, PLoS Pathog, 2024, 20(12): e1012770.
25. Li H#, Liu P#, Dong H#, Dekker A, Harmsen MM, Guo H*, Wang X*, Sun S*. Foot-and-mouth disease virus antigenic landscape and reduced immunogenicity elucidated in atomic detail, Nature Communications, 2024, 15(1): 8774.
26. Yu Q#, Liang D#, Fu W#, Zhang L#, Wang J#, Zhang Z#, Sun Y, Zhu D, Zheng B, Zhu L, Xiang Y, Zhao D*, Wang X*. p72 antigenic mapping reveals a potential supersite of vulnerability for African swine fever virus, Cell Discovery, 2024, 10(1): 80.
27. Liu J#, Zheng T#, Xu L#, Chen Z, Zhang K, Wang X, Xu X*, Li Y*, Sun Y*, Zhu L*. An improved method for the detection of double-stranded RNA suitable for quality control of mRNA vaccines, Protein Cell, 2024, 15(11): 791-795.
2023
28. Yue C#, Song W#, Wang L, Jian F, Chen X, Gao F, Shen Z, Wang Y, Wang X*, Cao Y*. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5, The Lancet Infectious Diseases, 2023, 23(3): 278-280.
29. Ou X#, Xu G#, Li P#, Liu Y#, Zan F, Liu P, Hu J, Lu X, Dong S, Zhou Y, Mu Z, Wu Z, Wang J, Jin Q, Liu P, Lu J, Wang X*, Qian Z*. Host susceptibility and structural and immunological insight of S proteins of two SARS-CoV-2 closely related bat coronaviruses, Cell Discovery, 2023, 9(1): 78.
30. Jian F#, Feng L#, Yang S#, Yu Y#, Wang L, Song W, Yisimayi A, Chen X, Xu Y, Wang P, Yu L, Wang J, Liu L, Niu X, Wang J, Xiao T, An R, Wang Y, Gu Q, Shao F, Jin R, Shen Z, Wang Y, Wang X*, Cao Y*. Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 synergistically enhances antibody evasion and ACE2 binding, PLOS Pathogens, 2023, 19(12): e1011868.
31. Li S#, Wu J#, Jiang W#, He H#, Zhou Y#, Wu W#, Gao Y#, Xie M#, Xia A, He J, Zhang Q, Han Y, Wang N, Zhu G, Wang Q, Zhang Z, Mayer CT, Wang K, Wang X*, Wang J*, Chen Z*, Jiang S*, Sun L*, Xia R*, Wang Q*. Characterization of cross-reactive monoclonal antibodies against SARS-CoV-1 and SARS-CoV-2: Implication for rational design and development of pan-sarbecovirus vaccines and neutralizing antibodies, J Med Virol, 2023, 95(2): e28440.
32. Cui Z#, Luo W#, Chen R#, Li Y#, Wang Z#, Liu Y#, Liu S, Feng L, Jia Z, Cheng R, Tang J, Huang W, Zhang Y, Liu H*, Wang X*, Li W*. Comparing T- and B-cell responses to COVID-19 vaccines across varied immune backgrounds, Signal Transduct Target Ther, 2023, 8(1): 179.
33. Dou Y#*, Xu K#, Deng YQ#, Jia Z#, Lan J#, Xu X#, Zhang G, Cao T, Liu P, Wang X, Wang X, Xu L, Du P, Qin CF, Liu H*, Li Y*, Wu G*, Wang K*, Lu B*. Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method, Antib Ther, 2023, 6(2): 76-86.
2022
34. Cui Z#, Liu P#, Wang N#, Wang L#, Fan K#, Zhu Q#, Wang K#, Chen R, Feng R, Jia Z, Yang M, Xu G, Zhu B, Fu W, Chu T, Feng L, Wang Y, Pei X, Yang P, Xie XS, Cao L*, Cao Y*, Wang X*. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron, Cell, 2022, 185(5): 860-871.
35. Wang K#, Jia Z#, Bao L#, Wang L#, Cao L#, Chi H#, Hu Y#, Li Q#, Jiang Y, Zhu Q, Deng Y, Liu P, Wang N, Wang L, Liu M, Li Y, Zhu B, Fan K, Fu W, Yang P, Pei X, Cui Z, Qin L, Ge P, Wu J, Liu S, Chen Y, Huang W, Qin CF*, Wang Y*, Qin C*, Wang X*. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants, Nature, 2022, 603(7903): 919-925.
36. Xiong Q#, Cao L#, Ma C#, Tortorici M#, Liu C, Si J, Liu P, Gu M, Walls A, Wang C, Shi L, Tong F, Huang M, Li J, Zhao C, Shen C, Chen Y, Zhao H, Lan K, Corti D, Veesler D*, Wang X*, Yan H*. Close relatives of MERS-CoV in bats use ACE2 as their functional receptors, Nature, 2022, 612(7941): 748-757.
37. Cao Y#*, Yisimayi A#, Jian F#, Song W#, Xiao T#, Wang L#, Du S#, Wang J#, Li Q#, Chen X#, Yu Y#, Wang P, Zhang Z, Liu P, An R, Hao X, Wang Y, Wang J, Feng R, Sun H, Zhao L, Zhang W, Zhao D, Zheng J, Yu L, Li C, Zhang N, Wang R, Niu X, Yang S, Song X, Chai Y, Hu Y, Shi Y, Zheng L, Li Z, Gu Q, Shao F, Huang W, Jin R, Shen Z*, Wang Y*, Wang X*, Xiao J*, Xie XS*. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection, Nature, 2022, 608(7923): 593-602.
38. Zhang Y#, Liang D#, Yuan F, Yan Y, Wang Z, Liu P, Yu Q, Zhang X, Wang X*, Zheng A*, Replication is the key barrier during the dual-host adaptation of mosquito-borne flaviviruses, PNAS, 2022, 119(12): e2110491119.
39. Li X#, Cui Z#, Hang F#, Chen Q#, Cao L#, Qiu H, Zhang N, Xu Y, Zhang R, Zhou C, Ye Q, Deng Y, Guo Y, Qin S, Fan K, Wang L, Jia Z, Cui Y*, Wang X*, Qin C*, A highly immunogenic live-attenuated vaccine candidate prevents SARS-CoV-2 infection and transmission in hamsters, Innovation(Camb), 2022, 3(2): 100221.
40. Wang L#, Fu W#, Bao L#, Jia Z#, Zhang Y#, Zhou Y#, Wu W, Wu J, Zhang Q, Gao Y, Wang K, Wang Q*, Qin C*, Wang X*, Selection and structural bases of potent broadly neutralizing antibodies from 3-dose vaccinees that are highly effective against diverse SARS-CoV-2 variants, including Omicron sublineages, Cell Research, 2022, 32(7): 691-694.
41. Deng W#, Lv Q#, Li F#, Liu J#, Song Z#, Qi F, Wei Q, Yu P, Liu M, Zhou S, Zhang Y, Gao H, Wang N, Jia Z, Gao K, Liu J, Xiao C, Shang H, Wang X*, Bao L*, Qin C*,Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques, Signal Transduct Target Ther, 2022, 7(1): 124.
42. Cao Y#*, Song W#, Wang L#, Liu P#, Yue C#, Jian F#, Yu Y, Yisimayi A, Wang P, Wang Y, Zhu Q, Deng J, Fu W, Yu L, Zhang N, Wang J, Xiao T, An R, Wang J, Liu L, Zhang N, Wang J, Xiao T, An R, Wang J, Liu L, Yang S, Niu X, Gu Q, Shao F, Hao X, Meng B, Gupta. R, Jin R, Wang Y, Xie X*, Wang X*. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75, Cell host & microbe, 2022, 30(11): 1527-1539.
43. Li Q#, Zhang L#, Liang Z#, Wang N#, Liu S#, Li T, Yu Y, Cui Q, Wu X, Nie J, Wu J, Cui Z, Lu Q, Wang X*, Huang W*, Wang Y*. Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses, Signal Transduct Target Ther, 2022, 7(1): 256.
44. Liu S#, Jia Z#, Nie J#, Liang Z#, Xie J, Wang L, Zhang L, Wang X*, Wang Y*, Huang W*. A broader neutralizing antibody against all the current VOCs and VOIs targets unique epitope of SARS-CoV-2 RBD, Cell Discovery, 2022, 8(1): 81.
45. Yang P#, Shi D#, Fu J, Zhang L, Chen R, Zheng B, Wang X, Xu S*, Zhu L*, Wang K*. Atomic Structures of Coxsackievirus B5 Provide Key Information on Viral Evolution and Survival, J Virol, 2022, 96(9): e0010522.
46. Chi H#, Wang L#, Liu C#, Cheng X#, Zheng H#, Lv L, Tan Y, Zhang N, Zhao S, Wu M, Luo D, Qiu H, Feng R, Fu W, Zhang J, Xiong X, Zhang Y, Zu S, Chen Q, Ye Q, Yan X, Hu Y, Zhang Z, Yan R, Yin J, Lei P, Wang W, Lang G*, Shao J*, Deng Y*, Wang X*, Qin C*. An Engineered IgG-VHH Bispecific Antibody against SARS-CoV-2 and Its Variants, Small Methods, 2022, 6(12): e2200932.
47. Wang M#, Sun Z#, Cui C#, Wang S, Yang D, Shi Z, Wei X, Wang P, Sun W, Zhu J, Li J, Du B, Liu Z, Wei L, Liu C, He X, Wang X*, Zhang X*, Wang J*. Structural Insights into Alphavirus Assembly Revealed by the Cryo-EM Structure of Getah Virus, Viruses, 2022, 14(2): 327.
48. Dong H#, Liu P#, Bai M, Wang K, Feng R, Zhu D, Sun Y, Mu S, Li H, Michiel H, Sun S*, Wang X*, Guo H*. Structural and molecular basis for foot-and-mouth disease virus neutralization by two potent protective antibodies, Protein Cell, 2022, 13(6): 446-453.
2021
49. Guo Q#, Zhao Y#, Li J#, Liu J#, Yang X#, Guo X, Kuang M, Xia H, Zhang Z, Cao L, Luo Y, Bao L, Wei X, Deng W, Wang N, Chen L, Chen J, Zhu H, Gao R, Qin, C*, Wang X*, You F*. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19, Cell Host and Microbe, 2021, 29(2): 222-235.
50. Zhu L#, Deng Y#, Zhang R#, Cui Z#, Sun C#, Fan C#, Xing X#, Huang W, Chen Q, Zhang N, Ye, Q, Cao T, Wang N, Wang L, Cao L, Wang H, Kong D, Ma J, Luo C, Zhang Y, Nie J, Sun Y, Lv Z, Shaw N, Li Q, Li X, Hu J, Xie L*, Rao Z*, Wang Y*, Wang X*, Qin C*. Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2, National Science Review, 2021, 8(3): nwaa297.
51. Zhao Y#, Kuang M#, Li J#, Zhu L#, Jia Z, Guo X, Hu Y, Kong J, Yin H, Wang X*, You F*. SARS-CoV-2 spike protein interacts with and activates TLR4, Cell Research, 2021, 31(7): 818-820.
52. Sun Y#, Wang L#, Feng R#, Wang N#, Wang Y#, Zhu D#, Xing X, Yang P, Zhang Y*, Li W*, Wang X*. Structure-based development of three- and four-antibody cocktails against SARS-CoV-2 via multiple mechanisms, Cell Research, 2021, 31(5): 597-600.
53. Zhang L#, Cao L#, Gao X#, Zheng B#, Deng Y#, Li J#, Feng R, Bian Q, Guo X, Wang N, Qiu H, Wang L, Cui Z, Ye Q, Chen G, Lu K, Chen Y, Chen Y, Pan H, Yu J, Yao W, Zhu B, Chen J, Liu Y, Qin C*, Wang X*, Zhu F*. A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2, National Science Review, 2021, 8(8): nwab053.
54. Sun S#, Gu H#, Cao L#, Chen Q#, Ye Q#, Yang G#, Li R#, Fan H#, Deng Y, Song X, Qi Y, Li M, Lan J, Feng R, Guo Y, Zhu N, Qin S, Wang L, Zhang Y, Zhou C, Zhao L, Chen Y, Shen M, Cui Y, Yang X, Wang X, Tan W, Wang H*, Wang X*, Qin C*. Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2, Nature Communications, 2021,12(1): 5654.
55. Feng R#, Wang L#, Shi D#, Zheng B, Zhang L, Hou H, Xia D, Cui L, Wang X*, Xu S*, Wang K*, Zhu L*. Structural basis for neutralization of an anicteric hepatitis associated echovirus by a potent neutralizing antibody, Cell Discovery, 2021, 7: 35.
56. Tai L#, Zhu G#, Yang M#, Cao L, Xing X, Yin G, Chan C, Qin C, Rao Z, Wang X*, Sun F*, Zhu Y*. Nanometer resolution in situ structure of the SARS-CoV-2 postfusion spike protein, PNAS, 2021, 118(48): e2112703118.
2020
57. Yao H#, Sun Y#, Deng Y#, Wang N#, Tan Y#, Zhang N#, Li X, Kong C, Xu Y, Chen Q, Cao T, Zhao H, Yan X, Cao L, Lv Z, Zhu D, Feng R, Wu N, Zhang W, Hu Y, Chen K, Zhang R, Lv Q, Sun S, Zhou Y, Yan R, Yang G, Sun X, Liu C, Lu X, Cheng L, Qiu H, Huang X, Weng T, Shi D, Jiang W, Shao J, Wang L, Zhang J, Jiang T, Lang G*, Qin C*, Li L*, Wang X*. Rational Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-SARS-CoVs Protection, Cell Research, 2020, 31(1): 25-36.
58. Wang N#, Sun Y#, Feng R#, Wang Y#, Guo Y#, Zhang L#, Deng Y, Wang L, Cui Z, Cao L, Zhang Y, Li W*, Zhu F*, Qin C*, Wang X*. Structure-based development of human antibody cocktails against SARS-CoV-2, Cell Research, 2020, 31(1): 101-103.
59. Lv Z#, Deng Y#, Ye Q#, Cao L#, Sun C#, Fan C#, Huang W, Sun S, Sun Y, Zhu L, Chen Q, Wang N, Nie J, Cui Z, Zhu D, Shaw N, Li X, Li Q, Xie L*, Wang Y*, Rao Z*, Qin C*, Wang X*. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody, Science, 2020, 369 (6510): 1505-1509.
60. Gao Q#, Bao L#, Mao H#, Wang L#, Xu K#, Yang M#, Li Y, Zhu L, Wang N, Zhe Lv, Gao H, Ge X, Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, Deng W, Li Y, Lu J*, Li C*, Wang X*, Yin W*, Zhang Y*, Qin Q*. Development of an inactivated vaccine candidate for SARS-CoV-2, Science, 2020,369 (6499): 77-81.
61. Wang K#, Zhu L#, Sun Y#, Li M, Zhao X, Cui L, Zhang L, George F. Gao, Zhai W, Zhu F*, Rao Z, Wang X*. Structures of Echovirus 30 in complex with its receptors inform a rational prediction for enterovirus receptor usage, Nature Communications, 2020, 11(1): 4421.
62. Wang K#, Zheng B#, Zhang L#, Cui L, Su X, Zhang Q, Guo Z, Guo Y, Zhang W, Zhu L*, Zhu F*, Rao Z*, Wang X*. Serotype specific epitopes identified by neutralizing antibodies underpin immunogenic differences in Enterovirus B, Nature Communications, 2020, 11(1): 4419.
63. Yang Y#, Yang P#, Wang N, Chen Z, Su D, Zhou ZH, Rao Z*, Wang X*. Architecture of the herpesvirus genome-packaging complex and implications for DNA translocation, Protein Cell, 2020, 11(5): 339-351.
64. Wang N#, Chen W#, Zhu L#, Zhu D, Feng R, Wang J, Zhu B, Zhang X, Chen X, Liu X, Yan R, Ni D, Grace Zhou G, Liu H*, Rao Z*, Wang X*. Structures of the portal vertex reveal essential protein-protein interactions for Herpesvirus assembly and maturation, Protein Cell, 2020, 11(5): 366-373.
2019
65. Wang N#, Zhao D#, Wang J#, Zhang Y#, Wang M, Gao Y, Li F, Wang J, Bu Z*, Rao Z*, Wang X*. Architecture of African swine fever virus and implications for viral assembly, Science, 2019, 366(6465): 640-644.
66. Cao L#, Liu P#, Yang P, Gao Q, Li H, Sun Y, Zhu L, Lin J, Dan S*, Rao Z*, Wang X*. Structural basis for neutralization of hepatitis A virus informs a rational design of highly potent inhibitors, PLoS Biology, 2019, 17(4): e3000229.
2018
67. Yuan S#, Wang J#, Zhu D#, Wang N, Gao Q, Chen W, Wang J*, Zhang X*, Liu H*, Rao Z*, Wang X*. Cryo-EM structure of a Herpesvirus capsid at 3.1A, Science, 2018, 360 (6384): 48-58.
68. Zhu L#*, Sun Y#, Fan J#, Zhu B, Cao L, Gao Q, Zhang Y*, Liu H, Rao Z*, Wang X*. Structures of Coxsackievirus A10 unveil the molecular mechanisms of receptor binding and viral uncoating, Nature Communications, 2018, 9(1): 4985.
69. Wang J#, Yuan S#, Zhu D#, Tang H, Wang N, Chen W, Gao Q, Li Y, Wang J, Liu H*, Zhang X*, Rao Z*, Wang X*. Structure of the herpes simplex virus type 2 C-capsid with capsid-vertex-specific component, Nature Communications, 2018, 9: 3668.
70. Qiu X#, Lei Y#, Yang P, Gao Q, Wang N, Cao L, Yuan S, Huang X, Deng Y, Ma W, Ding T, Zhang F, Wu X, Hu J, Liu S, Qin C, Wang X*, Xu Z*, Rao Z*. Structural basis for neutralization of Japanese encephalitis virus by two potent therapeutic antibodies, Nature Microbiology, 2018, 3: 287-294.
71. Huo Y#*, Li T, Wang N, Dong Q, Wang X*, Jiang T*. Cryo-EM structure of Type III-A CRISPR effector complex, Cell Research, 2018, 28: 1195-1197.
72. Zhu L#, Xu K#, Wang N#, Cao L, Wu J, Gao Q, Fry E.E, Stuart D.I, Rao Z, Wang J, Wang X*. Neutralization Mechanisms of Two Highly Potent Antibodies against Human Enterovirus 71, mBio, 2018, 9: e01013-18.
2017
73. Wang X#*, Zhu L#, Dang M#, Hu Z#, Gao Q, Yuan S, Sun Y, Zhang B, Ren J, Kotecha A, Walter T.S, Wang J*, Fry E.E*, Stuart D.I*, Rao Z*. Potent neutralization of hepatitis A virus reveals a receptor mimic mechanism and the receptor recognition site, Proc.Natl.Acad.Sci.USA, 2017, 114: 770-775.
74. Wang X#*, Li S#, Zhu L#, Nian Q#, Yuan S, Gao Q, Hu Z, Ye Q, Li X, Xie D, Shaw N, Wang J, Walter T.S, Huiskonen J.T, Fry E.E, Qin C*, Stuart D.I*, Rao Z*. Near-atomic structure of Japanese encephalitis virus reveals critical determinants of virulence and stability, Nature Communications, 2017, 8: 14.
75. Zhang X#, Yang P#, Wang N, Zhang J, Li J, Guo H, Yin X, Rao Z, Wang X*, Zhang L*. The binding of a monoclonal antibody to the apical region of SCARB2 blocks EV71 infection, Protein & Cell, 2017, 8: 590-600.
(From Xiangxi Wang, November 16, 2026)
